191 results about "Airway inflammation" patented technology

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Methods and pharmaceutical compositions for treating allergen-induced airway inflammation. The method includes administering a therapeutically effective amount of a pharmaceutical composition comprising a Dermatophoides pteronyssinus group 2 (Dp2) epitope peptide and a pharmaceutically acceptable carrier to an individual having allergen-induced airway inflammation, in a manner consistent with local nasal immunotherapy.

A method for management of asthma and other respiratory conditions is disclosed. This method uses exhaled nitric oxide readings to measure airway inflammation, thereby allowing precise titration of medication. The present invention can also be used to measure patient compliance with prescribed treatment regimes.

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and/or designing agents capable of modulating activin mediated regulation of the inflammatory response.

The invention relates to a EBC detection as a detection technique completely without wound, with important use value for airway inflammation. A fourway gaspath solves the automatic separation of entrance of expired air, exit of expired air, inspired air and spit residue. The upbending design and 'claw type' of the exit pipeline of the expired air can solve the effect of spit residue from the expired air on refrigeration area. A singlechip system detects the expired air amount and the condensing temperature is set to quantify the collection of the condensate of expired air, so as to quantitatively evaluate change and degree of states such as oxidation stress, inflammation and the like in airway of a variety of respiratory disease.

The present invention provides for uses of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in the treatment of asthma or airway inflammation in an individual in need thereof. The present invention also provides for use of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in reducing accumulation in lungs of inflammatory cells in an individual in need thereof.

An herbal composition includes Dioscorea opposita, Nelumbo nucifera seeds, Euryale ferox seeds, Poria cocos, Diospyros kaki, Prunus dulcis, Mentha piperita leaves, and Panax quinquefolius. A method for treatment of airway inflammation in a mammal includes administering to the mammal in need of such treatment the aforesaid herbal composition.

Disclosed are compositions comprising an Fc portion of IgE coupled to an agent. For example, disclosed are compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic. These compositions can be used as a vaccine or an immunotherapeutic. Thus, these compositions can modulate the immune system by both increasing and decreasing the immune response. The Fc portion of IgE can bind to CD23 and transport the antigen or immunotherapeutic across airway epithelial cells. Disclosed are methods of treating airway inflammation with compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic.

Compositions and methods for treating or preventing respiratory disorders and airway inflammation in an animal are disclosed. In one embodiment, the respiratory disorder is asthma. In one embodiment, the airway inflammation is asthma-related. In one embodiment, the respiratory disorder is cystic fibrosis. The method comprises administering an electrolyzed saline solution to the animal. In one embodiment, the electrolyzed saline solution comprises about 0.1 ppm to about 100 ppm ozone and one or more active species selected from the group consisting of: about 5 ppm to about 300 ppm of at least one active chlorine species, about 0.1 ppm to about 300 ppm of at least one active oxygen species, about 5 ppm to about 300 ppm active hydrogen species, and combinations thereof. A mouse model of cystic fibrosis and methods of screening pharmaceutical agents are also provided.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.

Provided herein are methods and compositions for modulating signal transduction pathways by regulating the expression and/or activity of Midline-1, enabling the inhibition of airways inflammation, the inhibition of airways hyperresponsiveness, the inhibition of rhinovirus-associated inflammation, and reductions in cytokine and chemokine release. Methods and compositions disclosed herein facilitate the treatment and prevention of conditions associated with airway inflammation, airway tissue remodelling and rhinovirus-associated inflammation and symptoms, manifestations and exacerbations thereof, in particular of allergic diseases such as allergic airways diseases including asthma.

The invention relates to a novel application of formononetin in the medical science, in particular to the application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma. Pharmacological test result shows that the formononetin participates in reducing the allergic airway inflammation of model animals/occurring and developing of asthma lesion; reducing the of damage inflammatory factor to the human bronchial epithelial cell in vitro and the formononetin can be used for preparing the medicine for treating airway inflammation diseases, such as asthma, bronchitis, capillary bronchitis and air or non-air idiotoxin or inflammatory or non-inflammatory of irritant; and specifically, the formononetin has the application in preparing medicine for treating allergic airway inflammation and asthma disease.